Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Rectal Neoplasms 29Esophageal Neoplasms 18Squamous Cell Carcinoma of Head and Neck 15Carcinoma, Non-Small-Cell Lung 14Nasopharyngeal Carcinoma 12Uterine Cervical Neoplasms 11Head and Neck Neoplasms 11Pancreatic Neoplasms 8Oropharyngeal Neoplasms 8Lung Neoplasms 6Glioblastoma 6Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Mouth Neoplasms 4Hypopharyngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 4Adenocarcinoma 4Radiation Injuries 3Pathologic Complete Response 3Carcinoma 3Breast Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms 2Nasopharyngeal Neoplasms 2NSCLC 2Lymphoma 2Lymphatic Metastasis 2

Interventions

Immunotherapy 2anlotinib 1Radiotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced Non-small Cell Lung Cancer × Chemoradiotherapy × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡